What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? a systematic review and economic evaluation

Health Technology Assessment

Volumn 18, Issue 33, 2014, Pages 1-119

  Leaviss, Joanna ^a   Sullivan, William ^a   Ren, Shijie ^a   Everson Hock, Emma ^a   Stevenson, Matt ^a   Stevens, John W ^a   Strong, Mark ^a   Cantrell, Anna ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CYTISINE; NICOTINE PATCH; PLACEBO; VARENICLINE; ALKALOID; AZOCINE DERIVATIVE; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; QUINOLIZINE DERIVATIVE; QUINOXALINE DERIVATIVE;

ABNORMAL DREAMING; ARTICLE; ASTHMA; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; HEADACHE; HUMAN; INSOMNIA; ISCHEMIC HEART DISEASE; LUNG CANCER; NAUSEA; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SMOKING CESSATION; SYSTEMATIC REVIEW; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT; ADULT; AGED; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED; NATIONAL HEALTH SERVICE; PROCEDURES; SMOKING; UNITED KINGDOM;

ADULT; AGED; ALKALOIDS; AZOCINES; BENZAZEPINES; COST-BENEFIT ANALYSIS; GREAT BRITAIN; HUMANS; MIDDLE AGED; NICOTINIC AGONISTS; QUALITY-ADJUSTED LIFE YEARS; QUINOLIZINES; QUINOXALINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING; SMOKING CESSATION; STATE MEDICINE;

EID: 84901368770     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta18330     Document Type: Article

References (126)

1. Peto R. Smoking and death: the past 40 years and the next 40. BMJ 1994;309:937-939. http://dx.doi.org/10.1136/bmj.309.6959.937
2. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA 2004;291:1238-1245. http://dx.doi.org/10.1001/jama.291.10.1238
3. Royal College of Physicians. Nicotine Addiction in Britain: a Report of the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians; 2000.
4. Mukherjee D, Yadav JS. Update on peripheral vascular diseases: From smoking cessation to stenting. Cleve Clin J Med 2001;68:723-733. http://dx.doi.org/10.3949/ccjm.68.8.723
5. Musk AW, de Klerk NH. History of tobacco and health. Respirology 2003;8:286-290.
6. Office for National Statistics (ONS). General Household Survey 2004. London: National Statistics; 2013.
7. Scarborough P, Bhatnagar P, Wickramasinghe KK, Allender S, Foster C, Rayner M. The economic burden of ill health due to diet, physical inactivity, smoking, alcohol and obesity in the UK: an update to 2006-07 NHS costs. J Public Health 2011;33:527-535.
8. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004;4:CD000031. http://dx.doi.org/10.1002/14651858.CD000031
9. West R. Addressing regulatory barriers to licensing nicotine products for smoking reduction. Addiction 2000;95(Suppl. 1):S29-S34. http://dx.doi.org/10.1046/j.1360-0443.95.1s1.4.x
10. Stead LF, Hartmann-Boyce J, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev 2013;8:CD002850. http://dx.doi.org/10.1002/14651858.CD002850
11. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev 2005;2:CD001007. http://dx.doi.org/10.1002/14651858.CD001007
12. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005;2:CD001292. http://dx.doi.org/10.1002/14651858.CD001292
13. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;1:CD000146. http://dx.doi.org/10.1002/14651858. CD000146.pub3
14. Hughes JR, Stead, LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007;1:CD000031. http://dx.doi.org/10.1002/14651858.CD000031
15. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012;4:CD006103. http://dx.doi.org/10.1002/14651858.CD006103.pub2
16. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63. [Erratum published in JAMA 2006;296:1355]. http://dx.doi.org/10.1001/jama.296.1.56
17. West R, Zatonski W, Cedzynska M, Lewandowska D, Pazik J, Aveyard P, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011;365:1193-1200. http://dx.doi.org/10.1056/NEJMoa1102035
18. Etter JF, Lukas RJ, Benowitz NL, West R, Dresler CM. Cytisine for smoking cessation: a research agenda. Drug Alcohol Depend 2008;92:3-8. http://dx.doi.org/10.1016/j.drugalcdep.2007.06.017
19. BNF. 2013. www.medicinescomplete.com/mc/bnf/current/PHP3209-champix.htm#PHP3209-champix (accessed 18 April 2013).
20. Zatonski W, Cedzynska M, Tutka P, West R. An uncontrolled trial of cytisine (Tabex) for smoking cessation. Tob Control 2006;15:481-484. http://dx.doi.org/10.1136/tc.2006.016097
21. West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005;100:299-303. http://dx.doi.org/10.1111/j.1360-0443.2004.00995.x
22. Hughes JR. Motivating and helping smokers to stop smoking. J Gen Intern Med 2003;18:1053-1057. http://dx.doi.org/10.1111/j.1525-1497.2003.20640.x
23. West R, Owen L. Estimates of 52-week Continuous Abstinence Rates Following Selected Smoking Cessation Interventions in England. Version 2. 2012 www.smokinginengland.info/reports (accessed 4 March 2014).
24. McEwen A, Hajek P, McRobbie H, West R. Manual of Smoking Cessation. Oxford: Blackwell Publishing; 2006.
25. West R, May S, West M, Croghan E, McEwan A. Performance of English stop smoking services in first 10 years: analysis of service monitoring data. BMJ 2013;347:f4921. http://dx.doi.org/10.1136/bmj.f4921
26. Hajek P, McRobbie H, Myers K. Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. Thorax 2013;68:1037-1042. http://dx.doi.org/10.1136/thoraxjnl-2012-203035
27. Leung LK, Patafio FM, Rosser WW. Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysis. BMC Clin Pharmacol 2011;11:15. http://dx.doi.org/10.1186/1472-6904-11-15
28. Tonstad S, Davie, S, Flammer M, Russ C, Hughes J. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis. Drug Safe 2010;33:289-301. http://dx.doi.org/10.2165/11319180-000000000-00000
29. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011;183:1359-1366. http://dx.doi.org/10.1503/cmaj.110218
30. Prochaska JJ. Review: Varenicline for tobacco cessation does not increase CV serious adverse events. Ann Intern Med 2012;157:21.
31. West CH, Weiss JM. A selective test for antidepressant treatments using rats bred for stress-induced reduction of motor activity in the swim test. Psychopharmacology 2005;182:9-23. http://dx.doi.org/10.1007/s00213-005-0048-x
32. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928. http://dx.doi.org/10.1136/bmj.d5928
33. Lunn D, Thomas A, Best N, Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000;10:325-337.
34. Brooks S, Gelman A. Alternative methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998;7:434-45.
35. McCullagh P. Generalized Linear Models. London: Chapman & Hall/CRC; 1989.
36. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 2009;6:e1000097. http://dx.doi.org/10.1371/journal.pmed.1000097
37. Wong J, Abrishami A, Yang Y, Zaki A, Friedman Z, Selby P, et al. A perioperative smoking cessation intervention with varenicline: a double-blind, randomized, placebo-controlled trial. Anesthesiology 2012;117:755-764. http://dx.doi.org/10.1097/ALN.0b013e3182698b42
38. de Dios MA, Anderson BJ, Stanton C, Audet DA, Stein M. Project Impact: A pharmacotherapy pilot trial investigating the abstinence and treatment adherence of Latino light smokers. J Subst Abuse Treat 2012;43:322-330. http://dx.doi.org/10.1016/j.jsat.2012.01.004
39. Heydari G, Talischi F, Tafti SF, Masjedi MR. Quitting smoking with varenicline: parallel, randomised efficacy trial in Iran. Int J Tuberc Lung Dis 2012;16:268-272. http://dx.doi.org/10.5588/ijtld.11.0183
40. Pfizer Inc. Smoking Cessation Study for Patients with Schizophrenia or Schizoaffective Disorder. 2011. http://clinicaltrials.gov/ct2/show/NCT00644969?term=NCT00644969&rank=1
41. Williams JM, Anthenelli RM, Morris CD, Treadow J, Thompson JR, Yunis C, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2012;73:654-660. http://dx.doi.org/10.4088/JCP.11m07522
42. Scharfenberg G, Benndorf S, Kempe G. Cytisine (Tabex) as a pharmaceutical aid in stopping smoking. Dtsch Gesundheitsw 1971;26:463-465.
43. Vinnikov D, Brimkulov N, Burjubaeva A. A double-blind, randomised, placebo-controlled trial of cytisine for smoking cessation in medium-dependent workers. J Smok Cessat 2008;3:57-62. http://dx.doi.org/10.1375/jsc.3.1.57
44. Swan G, McClure JB, Jack LM, Zbikowski SM, Javitz HS, Catz SL, et al. Behavioural Counselling and varenicline tretament for smoking cessation. Am J Prev Med 2010;38:482-490.
45. Tonstad S. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist. J Cardiovasc Nurs 2006;21:433-436. http://dx.doi.org/10.1097/00005082-200611000-00004
46. Aubin H-J, Bobak A, Britton JR, Oncken C, Billing CB, Gong J, et al. Varenicline compared with transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008;63:717-724.
47. Bolliger CT, Issa JS, Posadas VR, Safwat T, Abreu P, Correia EA, et al. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study. Clin Ther 2011;33:465-477. http://dx.doi.org/10.1016/j.clinthera.2011.04.013
48. Gonzales D, Rennard S, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release buprion and placebo for smoking cessation. A randomized trial. JAMA 2006;296:47-55.
49. Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves K. Efficacy and tolerability of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40 week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29:1040-1056.
50. Niaura R, Taylor Hays J, Jorenby DE, Leone FT, Pappas JE, Reeves KR, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomised controlled trial. Curr Med Res Opin 2008; 24:1931-1941.
51. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist. Arch Intern Med 2006;166:1561-1577. http://dx.doi.org/10.1001/archinte.166.15.1561
52. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006;166:1571-1577. http://dx.doi.org/10.1001/archinte.166.15.1571
53. Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, et al. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. Nicotine Tob Res 2012;14:343-350. http://dx.doi.org/10.1093/ntr/ntr220
54. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: A randomized trial. Circulation 2010;121:221-229. http://dx.doi.org/10.1161/CIRCULATIONAHA.109.869008
55. Smith B, Carson K, Brinn M, Labiszewski N, Peters M, Fitridge R, et al. Smoking Termination Opportunity for inPatients (STOP): superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 12-month randomised controlled trial. Thorax 2013;68,485-486. http://dx.doi.org/10.1136/thoraxjnl-2012-202484
56. Steinberg MB, Randall J, Greenhaus S, Schmelzer AC, Richardson DL, Carson JL. Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline. Addict Behav 2011;36:1127-1132. http://dx.doi.org/10.1016/j.addbeh.2011.07.002
57. Tashkin DP, Rennard S, Hays J, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD. Chest 2011;139:591-599. http://dx.doi.org/10.1378/chest.10-0865
58. Tsai S-T, Cho H-J, Cheng H-S, Kim C-H, Hsueh, K-C, Billing CB, et al. A randomized, placebo-controlled trial of varenicline, a selective α4β2, nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007;29:1027-1039. http://dx.doi.org/10.1016/j.clinthera.2007.06.011
59. Tsukahara H, Noda K, Saku K. A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers. Circ J 2010;74:771-78. http://dx.doi.org/10.1253/circj.CJ-09-0803
60. Wang C, Xiao D, Chan KPW, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: A placebo-controlled, randomized study. Respirology 2009;14:384-392. http://dx.doi.org/10.1111/j.1440-1843.2008.01476.x
61. Williams KE, Reeves KR, Billing CB, Pennignton AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007;23:793-801. http://dx.doi.org/10.1185/030079907X182185
62. Annemans L, Nackaerts K, Bartsch, P, Prignot J, Marbaix S. Cost-effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis. Clin Drug Investig 2009;29:655-665. http://dx.doi.org/10.2165/11317730-000000000-00000
63. Hoogendoorn M, Welsing P, Rutten-van Molken MP. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008;24:51-61. http://dx.doi.org/10.1185/030079907X242917
64. Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomaki T. Cost-effectiveness of varenicline compared with bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Curr Med Res Opin 2010;26:549-560.
65. Pfizer. Manufacturers Submission for NICE STA of Varenicline for Smoking Cessation. Tadworth, Surrey: Pfizer Ltd; 2007.
66. Bae JY, Kim CH, Lee EK. Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea. Value Health 2009;12(Suppl. 3):S70-3. http://dx.doi.org/10.1111/j.1524-4733.2009.00631.x
67. Bolin K, Mork AC, Wilson K. Smoking-cessation therapy using varenicline: the cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence. J Eval Clin Pract 2009;15:478-485. http://dx.doi.org/10.1111/j.1365-2753.2008.01045.x
68. Bolin K, Wilson K, Benhaddi H, de NE, Marbaix S, Mork AC, et al. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation - results from four European countries. Eur J Public Health 2009;19:650-654. http://dx.doi.org/10.1093/eurpub/ckp075
69. Bolin K, Mork AC, Willers S, Lindgren B. Varenicline as compared with bupropion in smoking-cessation therapy-cost-utility results for Sweden 2003. Respir Med 2008;102:699-710. http://dx.doi.org/10.1016/j.rmed.2007.12.018
70. Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline compared with existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics 2008;26:497-511.
71. Knight C, Howard P, Baker, CL, Marton JP. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. Value Health 2010;13:209-214. http://dx.doi.org/10.1111/j.1524-4733.2009.00672.x
72. Vemer P, Rutten-van Molken MP. Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. Value Health 2010;13:230-241. http://dx.doi.org/10.1111/j.1524-4733.2009.00612.x
73. European Medicines Agency. EPAR Summary for the Public, Champix (Varenicline). EMA/266058/2011. London: European Medicines Agency; 2012.
74. NICE. Guide to the Methods of Technology Appraisal. London: NICE; 2008.
75. Office for National Statistics (ONS). Population Trends. Newport: ONS; 2006.
76. Office for National Statistics (ONS). General Household Survey, 2004 Report - Smoking and Drinking. Newport: ONS; 2004.
77. Government Actuary's Department. Historic Interim Life Tables; Interim Life Tables 2002-2004. 2013. www.gad.gov.uk/Demography%20Data/Life%20Tables/historic_interim_life_tables.html (accessed 1 March 2013).
78. Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA 2000;284:706-712. http://dx.doi.org/10.1001/jama.284.6.706
79. Cassino C, Ito K, Bader I, Ciotoli C, Thurston G, Reibman J. Cigarette smoking and ozone-associated emergency department use for asthma by adults in New York City. Am J Respir Crit Care Med 1999;159:1773-1779. http://dx.doi.org/10.1164/ajrccm.159.6.9809042
80. Soriano JB, Maier WC, Egger P, Visick G, Thakrar B, Sykes J, et al. Recent trends in physician diagnosed COPD in women and men in the UK. Thorax 2000;55:789-794. http://dx.doi.org/10.1136/thorax.55.9.789
81. Forman D, Stockton D, Moller H, Quinn M, Babb P, De AR, et al. Cancer prevalence in the UK: results from the EUROPREVAL study. Ann Oncol 2003;14:648-654. http://dx.doi.org/10.1093/annonc/mdg169
82. Office for National Statistics (ONS). Registrations of Cancer Diagnosed in 2003, England. Newport: ONS; 2005. Series MB1, 34.
83. Asthma UK. Where Do We Stand?: Asthma in the UK Today. London: Asthma UK; 2004.
84. Hoskins G, McCowan C, Neville RG, Thomas GE, Smith B, Silverman S. Risk factors and costs associated with an asthma attack. Thorax 2000;55:19-24. http://dx.doi.org/10.1136/thorax.55.1.19
85. British Heart Foundation. Coronary Heart Disease Statistics fact sheet. London: British Heart Foundation; 2006.
86. Volmink JA, Newton JN, Hicks NR, Sleight P, Fowler GH, Neil HA. Coronary event and case fatality rates in an English population: results of the Oxford myocardial infarction incidence study. The Oxford Myocardial Infarction Incidence Study Group. Heart 1998;80:40-44.
87. Office for National Statistics. Health Statistics Quarterly, No.12. London: The Stationery Office; 2001.
88. Wetter DW, Cofta-Gunn L, Fouladi RT, Cinciripini PM, Sui D, Gritz ER. Late relapse/sustained abstinence among former smokers: a longitudinal study. Prev Med 2004;39:1156-1163. http://dx.doi.org/10.1016/j.ypmed.2004.04.028
89. Hind D, Tappenden P, Peters J, Kenjegalieva K. Varenicline in the management of smoking cessation: a single technology appraisal. Health Technol Assess 2009;13(Suppl. 2).
90. Hawkins J, Hollingworth W, Campbell R. Long-term smoking relapse: a study using the british household panel survey. Nicotine Tob Res 2010;12:1228-1235. http://dx.doi.org/10.1093/ntr/ntq175
91. Krall EA, Garvey AJ, Garcia RI. Smoking relapse after 2 years of abstinence: findings from the VA Normative Aging Study. Nicotine Tob Res 2002;4:95-100. http://dx.doi.org/10.1080/14622200110098428
92. Godfrey C, Parrott S, Coleman T, Pound E. The cost-effectiveness of the English smoking treatment services: evidence from practice. Addiction 2005;100(Suppl. 2):70-83. http://dx.doi.org/10.1111/j.1360-0443.2005.01071.x
93. Yudkin P, Hey K, Roberts S, Welch S, Murphy M, Walton R. Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch. BMJ 2003;327:28-29. http://dx.doi.org/10.1136/bmj.327.7405.28
94. Britton M. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respir Med 2003;97(Suppl. C):S71-S79. http://dx.doi.org/10.1016/S0954-6111(03)80027-6
95. Flack S, Taylor M, Trueman P. Cost-effectiveness of Interventions for Smoking Cessation. York: York Health Economics Consortium, University of York; 2007.
96. Sanderson H, Spiro S. Cancer of the lung. In: Stevens A, Raftery J, Mant J, Simpson S, editors. Health Care Needs Assessment: the Epidemiologically Based Needs Assessment Reviews. 2nd edn. Abingdon: Radcliffe Publishing; 2004. pp. 503-548.
97. McMurray J, Hart W, Rhodes G. An evaluation of the cost of heart failure to the National Health Service in the UK. J Med Econ 1993;6:99-110.
98. Simpson EL, Stevenson MD, Scope A, Poku A, Minton J, Evans P. Echocardiography in Newly Diagnosed Atrial Fibrillation Patients: A Systematic Review and Economic Evaluation. Sheffield: School of Health and Related Research (ScHARR) Technology Assessment Group, The University of Sheffield; 2011.
99. Rivero-Arias O, Ouellet M, Gray A, Wolstenholme J, Rothwell PM, Luengo-Fernandez R. Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Making 2010;30:341-354. http://dx.doi.org/10.1177/0272989X09349961
100. Curtis L. Unit Costs of Health and Social Care. Canterbury: Personal Social Services Research Unit, The University of Kent; 2012.
101. Briggs A, Sculpher M, Claxton K. Decision Modelling for Health Economic Evaluation (Handbooks for Health Economic Evaluation). Oxford: Oxford University Press; 2006.
102. Stapleton JA, West RA. Direct Method and ICER Tables for the Estimation of the Cost-Effectiveness of Smoking Cessation Interventions in General Populations: Application to a New Cytisine Trial and Other Examples. Oxford: Oxford University Press; 2012.
103. Tabex Tablets 2013 www.tabextablets.co.uk/(accessed 18 March 2013).
104. Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health 2010;13:509-518. http://dx.doi.org/10.1111/j.1524-4733.2010.00700.x
105. Trippoli S, Vaiani M, Lucioni C, Messori A. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics 2001;19:855-863.
106. Szende A, Svensson K, Stahl E, Meszaros A, Berta GY. Psychometric and utility-based measures of health status of asthmatic patients with different disease control level. Pharmacoeconomics 2004;22:537-547. http://dx.doi.org/10.2165/00019053-200422080-00005
107. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 1998;29:1083-91. http://dx.doi.org/10.1161/01.STR.29.6.1083
108. Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics 2003;21:191-200. http://dx.doi.org/10.2165/00019053-200321030-00004
109. Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess the cost-effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005;23:619-637. http://dx.doi.org/10.2165/00019053-200523060-00008
110. Hay JW, Sterling KL. Cost-effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. Pharmacoeconomics 2005;23:133-141. http://dx.doi.org/10.2165/00019053-200523020-00005
111. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ 1996;5:513-524. http://dx.doi.org/10.1002/(SICI)1099-1050(199611)5:6%3C513::AID-HEC237%3E3.0.CO;2-9
112. Felli JC, Hazen GB. Sensitivity analysis and the expected value of perfect information. Med Decis Making 1998;18:95-109. http://dx.doi.org/10.1177/0272989X9801800117
113. Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical decision modeling. Med Decis Making 2004;24:207-227. http://dx.doi.org/10.1177/0272989X04263162
114. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-787. http://dx.doi.org/10.1002/hec.635
115. Robinson S, Harris H. Smoking and Drinking Among Adults 2009, A Report on the 2009 General Lifestyle Survey. Newport: Office for National Statistics; 2011.
116. Brown J, Michie S, West R. The case of Stop Smoking Services in England. Br J Psychiatry 2013;202:74-76.
117. Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG. Use of smoking-cessation treatments in the United States. Am J Prev Med 2008;34:102-111. http://dx.doi.org/10.1016/j.amepre.2007.09.033
118. West R, DiMarino ME, Gitchell J, McNeill A. Impact of UK policy initiatives on use of medicines to aid smoking cessation. Tob Control 2005;14:166-171. http://dx.doi.org/10.1136/tc.2004.008649
119. Vogt F, Hall S, Marteau TM. Understanding why smokers do not want to use nicotine dependence medications to stop smoking: qualitative and quantitative studies. Nicotine Tob Res 2008;10:1405-1413. http://dx.doi.org/10.1080/14622200802239280
120. Stevenson MD, Oakley J, Lloyd Jones M, Brennan A, Compston J, McCloskey E, et al. The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture. Med Decis Making 2009;29:678-689. http://dx.doi.org/10.1177/0272989X09336077
121. Woolacott NF, Jones L, Forbes CA, Mather LC, Sowden AJ, Song FJ, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. Health Technol Assess 2002;6(16).
122. Heitjan DF, Asch DA, Ray R, Rukstalis M, Patterson F, Lerman C. Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. Pharmacogenomics J 2008;8:391-399. http://dx.doi.org/10.1038/sj.tpj.6500492
123. Xenakis JG, Kinter ET, Ishak KJ, Ward AJ, Marton JP, Willke RJ, et al. A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data. Pharmacoeconomics 2011;29:497-510. http://dx.doi.org/10.2165/11589230-000000000-00000
124. Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med 2006;166:1553-1559. http://dx.doi.org/10.1001/archinte.166.15.1553
125. Gunnell D, Irvine D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009;339:b3805. http://dx.doi.org/10.1136/bmj.b3805
126. Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ 2012;344:e2856. http://dx.doi.org/10.1136/bmj.e2856